JP2022540553A - カンナビノイド系ポリマーマトリックスの形態のデバイス - Google Patents
カンナビノイド系ポリマーマトリックスの形態のデバイス Download PDFInfo
- Publication number
- JP2022540553A JP2022540553A JP2021573392A JP2021573392A JP2022540553A JP 2022540553 A JP2022540553 A JP 2022540553A JP 2021573392 A JP2021573392 A JP 2021573392A JP 2021573392 A JP2021573392 A JP 2021573392A JP 2022540553 A JP2022540553 A JP 2022540553A
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- active ingredient
- oil
- cbd
- oils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 85
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 24
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 93
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 239000011159 matrix material Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000000699 topical effect Effects 0.000 claims abstract description 14
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 82
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 82
- 229950011318 cannabidiol Drugs 0.000 claims description 82
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 82
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical group OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 81
- 239000003921 oil Substances 0.000 claims description 43
- 239000000341 volatile oil Substances 0.000 claims description 36
- 208000002193 Pain Diseases 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 21
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 17
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 17
- 239000004814 polyurethane Substances 0.000 claims description 15
- 229920002635 polyurethane Polymers 0.000 claims description 15
- 229920001169 thermoplastic Polymers 0.000 claims description 15
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- -1 fatty acid esters Chemical class 0.000 claims description 10
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 10
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 10
- 229960004242 dronabinol Drugs 0.000 claims description 9
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 8
- 244000246386 Mentha pulegium Species 0.000 claims description 8
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 8
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 8
- 235000001050 hortel pimenta Nutrition 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 7
- UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 claims description 6
- 241000208152 Geranium Species 0.000 claims description 6
- XTDYIOOONNVFMA-UHFFFAOYSA-N dimethyl pentanedioate Chemical compound COC(=O)CCCC(=O)OC XTDYIOOONNVFMA-UHFFFAOYSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 5
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 claims description 5
- 235000004722 Eucalyptus citriodora Nutrition 0.000 claims description 5
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 5
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 5
- 244000126014 Valeriana officinalis Species 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 5
- 239000001102 lavandula vera Substances 0.000 claims description 5
- 235000018219 lavender Nutrition 0.000 claims description 5
- 229930007744 linalool Natural products 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 235000016788 valerian Nutrition 0.000 claims description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 235000001053 badasse Nutrition 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 244000056931 lavandin Species 0.000 claims description 4
- 235000009606 lavandin Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000002773 monoterpene derivatives Chemical class 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940031439 squalene Drugs 0.000 claims description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 4
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 3
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 3
- 240000007551 Boswellia serrata Species 0.000 claims description 3
- 240000007436 Cananga odorata Species 0.000 claims description 3
- 241000218645 Cedrus Species 0.000 claims description 3
- 240000003538 Chamaemelum nobile Species 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 241001672694 Citrus reticulata Species 0.000 claims description 3
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 3
- 240000002319 Citrus sinensis Species 0.000 claims description 3
- 244000166675 Cymbopogon nardus Species 0.000 claims description 3
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 claims description 3
- 235000010695 Eucalyptus radiata Nutrition 0.000 claims description 3
- 240000003060 Eucalyptus radiata Species 0.000 claims description 3
- 239000004863 Frankincense Substances 0.000 claims description 3
- 244000308760 Helichrysum petiolatum Species 0.000 claims description 3
- 241000721662 Juniperus Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 241000378544 Melaleuca quinquenervia Species 0.000 claims description 3
- 244000179970 Monarda didyma Species 0.000 claims description 3
- 235000010672 Monarda didyma Nutrition 0.000 claims description 3
- 235000010679 Nepeta cataria Nutrition 0.000 claims description 3
- 240000009215 Nepeta cataria Species 0.000 claims description 3
- 235000011203 Origanum Nutrition 0.000 claims description 3
- 240000000783 Origanum majorana Species 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 235000002911 Salvia sclarea Nutrition 0.000 claims description 3
- 244000182022 Salvia sclarea Species 0.000 claims description 3
- 240000000513 Santalum album Species 0.000 claims description 3
- 235000008632 Santalum album Nutrition 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 3
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 claims description 3
- CJFLBOQMPJCWLR-UHFFFAOYSA-N bis(6-methylheptyl) hexanedioate Chemical compound CC(C)CCCCCOC(=O)CCCCC(=O)OCCCCCC(C)C CJFLBOQMPJCWLR-UHFFFAOYSA-N 0.000 claims description 3
- 229940100539 dibutyl adipate Drugs 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000000552 rheumatic effect Effects 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 239000001585 thymus vulgaris Substances 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003421 squalenes Chemical class 0.000 claims description 2
- 244000165852 Eucalyptus citriodora Species 0.000 claims 1
- 244000178870 Lavandula angustifolia Species 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229940052303 ethers for general anesthesia Drugs 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- GCTMVWJHICUMRV-UHFFFAOYSA-N octan-3-yl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(OC(CC)CCCCC)OC1=CC=CC=C1 GCTMVWJHICUMRV-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 35
- 238000003756 stirring Methods 0.000 description 19
- 239000004014 plasticizer Substances 0.000 description 13
- 239000000654 additive Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 229940065144 cannabinoids Drugs 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 244000025254 Cannabis sativa Species 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- 235000005607 chanvre indien Nutrition 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 7
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 7
- 235000009120 camo Nutrition 0.000 description 7
- 239000011487 hemp Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 240000004308 marijuana Species 0.000 description 7
- 239000010460 hemp oil Substances 0.000 description 6
- 238000001746 injection moulding Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 244000107602 Corymbia citriodora Species 0.000 description 4
- 244000165082 Lavanda vera Species 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 235000011624 Agave sisalana Nutrition 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000001510 arthropathic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- QYMGIIIPAFAFRX-UHFFFAOYSA-N butyl prop-2-enoate;ethene Chemical compound C=C.CCCCOC(=O)C=C QYMGIIIPAFAFRX-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229920006245 ethylene-butyl acrylate Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical group 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K13/00—Devices for grooming or caring of animals, e.g. curry-combs; Fetlock rings; Tail-holders; Devices for preventing crib-biting; Washing devices; Protection against weather conditions or insects
- A01K13/003—Devices for applying insecticides or medication
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K27/00—Leads or collars, e.g. for dogs
- A01K27/007—Leads or collars, e.g. for dogs with insecticide-dispensing means
-
- A—HUMAN NECESSITIES
- A44—HABERDASHERY; JEWELLERY
- A44C—PERSONAL ADORNMENTS, e.g. JEWELLERY; COINS
- A44C5/00—Bracelets; Wrist-watch straps; Fastenings for bracelets or wrist-watch straps
- A44C5/0007—Bracelets specially adapted for other functions or with means for attaching other articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/13—Phenols; Phenolates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L23/00—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- C08L23/02—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers not modified by chemical after-treatment
- C08L23/04—Homopolymers or copolymers of ethene
- C08L23/08—Copolymers of ethene
- C08L23/0846—Copolymers of ethene with unsaturated hydrocarbons containing other atoms than carbon or hydrogen atoms
- C08L23/0853—Vinylacetate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
- C08L75/04—Polyurethanes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Pest Control & Pesticides (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
-認可されたヘンプの品種は、フランスの公衆衛生法に記載されている。
-種および繊維のみを使用できる。ただし、花の使用は禁止されている。
-植物はデルタ-9-テトラヒドロカンナビノール(THC)の0.2%未満の含有量を有する必要がある。
-CBDベースの製品にTHCが含まれている場合は、どのような量であっても禁止されている。
-0.01%~10%のCBD分離株またはCBD油の
-0.5%~20%の相補的活性成分、
-0.1%~30%のベクター化添加剤の
-0%~50%の可塑化添加剤、
-EVAまたはTPUから選択されるqs100重量%の固体ポリマーマトリックスとして構成される。
-0.01%~10%のCBD分離株またはCBD油の
-0.5%~20%の相補的活性成分、
-0.5~15%のベクター化添加剤、
-0%~1.5%の抗酸化添加物、
-qs100%重量の固体EVAポリマーマトリックスとして構成される。
-0.1%~5%のCBD分離株、
-0.5重量%~15重量%の、精油および/または精油化合物の形態の活性成分、
-0.5%~15%のベクター化添加剤、
-5%~35%の可塑化添加剤、
-qs100%重量のTPU固体ポリマーマトリックスとして構成される。
-0.1%~5%のCBD分離株、
-0.5重量%~15重量%の、精油および/または精油化合物の形態の活性成分、
-1%~6%のベクター化添加剤、
-5%~35%の可塑化添加剤、
-qs100%重量のTPU固体ポリマーマトリックスとして構成される。
-0.1%~5%のCBD分離株、
-0.5重量%~15重量%の、精油および/または精油化合物、より好ましくはペパーミント精油の形態の活性成分、
-1%~6%のベクター化添加剤、より好ましくはスクワラン、
-5%~35%の可塑剤、好ましくはリン酸エチルヘキシルジフェニル、アジピン酸ジメチル、グルタル酸ジメチルおよびコハク酸ジメチルまたはグルタル酸ジメチルの混合物、
-TPUで構成されるqs100重量%の固体ポリマーマトリックスとして構成される。
3つの活性成分、すなわち、ヘンプ油、リナロール、およびメンソールは、周囲温度でビーカー中に次々と配置される。精製された亜麻仁油を添加して活性成分をよりよく分散させ、次にミリスチン酸イソプロピルを浸透促進剤として加える。これを棒磁石を使用して穏やかに攪拌し、鎮痛活性成分の溶液を形成する均質な混合物を得る。
活性成分、すなわち、カンナビノイドとバレリアン精油を豊富に含むヘンプ油を周囲温度でビーカー内に入れ、次にトランスキュートールVを浸透促進剤として添加する。これを棒磁石を使用して穏やかに攪拌し、リラックスする抗ストレス活性成分の溶液を形成する均質な混合物を得る。
ポリマーは、ポリマーの種類に応じて必要な温度(この場合、TPUの場合、約90℃~95℃)に予熱された反応器内に、活性成分をその中に組み込むためにネットワークが開くことを可能にする構造をポリマーに付与するのに十分な温度に配置する。穏やかに攪拌する。
-可塑化およびベクター化成分を秤量および混合し、均質化するように攪拌して、限界混合物を得る。
-周囲温度で攪拌しながら、第1の活性成分としてCBD分離株を添加し、限界の半透明混合物が得られるまで攪拌したままにする。
-共活性成分、この場合はペパーミント精油を添加し、均質化して均質な半透明の混合物を得る。
結果は、デバイスが安定であり、CBDを含む必要な活性成分を効果的に組み込むことを可能にしたことを示す。
ポリマーは、ポリマーの種類に応じて必要な温度(この場合、EVAの場合、約70℃)に予熱された反応器内に、活性成分をその中に組み込むためにネットワークが開くことを可能にする構造をポリマーに付与するのに十分な温度に配置する。穏やかに攪拌する。
-可塑化およびベクター化成分を秤量および混合し、均質化するように攪拌して、限界混合物を得る。
-周囲温度で攪拌しながら、第1の活性成分としてCBD分離株を添加し、限界の半透明混合物が得られるまで攪拌したままにする。
-共活性成分、この場合はペパーミント精油を添加し、均質化して均質な半透明の混合物を得る。
本発明によるデバイスに安定的に組み込まれた活性成分が、デバイスが適用される対象を治療するために、少なくとも4週間の期間にわたっても効果的に送達され得ることを検証することができるように、出願人によってインビトロ試験が開発された。
1)首輪を使用前に巻き上げたままにするシートを取り外す。
2)首輪の初期重量を測量し、記録する。
3)首輪を250mlのフラスコに入れる。
4)首輪が完全に浸かるまでオリーブ油を添加し、測量する。
5)動態試験の間ずっと攪拌し続ける。
6)分析のために決定された各時間(例えば、D1、D3、D7、D10、D14、D21、D28)に、油の試料を採取する。
7)この試料の油から適切な溶媒を使用してCBDを抽出する。
8)HPLCを使用して抽出物を分析し、培地中に放出されたCBDの量を定量化する。ある量を、最初に組み込まれた量に対するmgまたはパーセンテージとして得た。分析は、認定されたCBD規格からの外部較正を使用して、逆相HPLCを使用して行われる。
9)経時的な油中CBD放出曲線をプロットする。
首輪の形態の実施例10に従う本発明によるデバイスは、CBDを含む必要な活性成分を効果的かつ安定的に組み込むことができた。上記の結果および図1の対応する曲線は、イヌなどの処置対象の長期処置のために、時間の経過とともにCDBが徐々に放出されることを示している。28日時点で、プラトーに到達しておらず、放出が継続されていることに留意されたい。
首輪の形態の実施例5に従う本発明によるデバイスは、CBDを含む必要な活性成分を効果的に組み込むことができた。上記の結果および図2における対応する曲線は、時間の経過とともにCDBが徐々に放出されることを示している。進行中の試験では、10日間にわたって放出を評価することができる。試験が継続されており、曲線の傾きは、経時的に継続的な放出について容易に推定できることを理解されたい。
首輪の形態の実施例11従う本発明によるデバイスは、CBDを含む必要な活性成分を効果的に組み込むことができた。上記の結果および図2における対応する曲線は、時間の経過とともにCDBが徐々に放出されることを示している。進行中の試験では、10日間にわたって放出を評価することができる。試験が継続されており、曲線の傾きは、経時的に継続的な放出について容易に推定できることを理解されたい。
Claims (14)
- ポリマーが、エチレンビニルアセテートコポリマーおよびポリウレタンからなる群から選択されることを特徴とする単層ポリマーマトリックスから形成される局所適用のためのデバイスであって、前記マトリックスがまた、少なくとも1つのカンナビノイド誘導体と、前記マトリックスの総重量の0.5%~20%の精油または精油のモノテルペン誘導体と、を含むことを特徴とする、デバイス。
- 前記ポリマーが、非接着性であることを特徴とする、請求項1に記載のデバイス。
- 前記ポリマーが、エチレンビニルアセテートコポリマーであることを特徴とする、請求項1または2に記載のデバイス。
- 前記ポリマーが、ポリウレタンであることを特徴とする、請求項1または2に記載のデバイス。
- 前記カンナビノイド誘導体が、デルタ-9-テトラヒドロカンナビノール(THC)を含まないカンナビジオール(CBD)であることを特徴とする、請求項1~4のいずれか一項に記載のデバイス。
- 前記精油または精油のモノテルペン誘導体が、ラベンダー、ラバンジン、イタリアヘリクリサム、スギ、レモン、シトロネラ、ニンジン、ショウガ、ニアウリ、スイートオレンジ、クローブ、ユーカリシトリオドラ、ユーカリラジアータ、ペパーミント、ゼラニウム、バレリアン、ネペタカタリア、カモミール、イランイラン、クラリーセージ、マンダリン、サンダルウッド、ベルガモット、マージョラム、フランキンセンス、ゼラニウム、タイム、ジュニパー、またはそれらの混合物のリナロール、メンソール、または精油から選択されることを特徴とする、請求項1~5のいずれか一項に記載のデバイス。
- 有機起源の油、合成起源の油、鉱物起源の油、植物起源の油、コハク酸エステル、グルタル酸エステル、およびアジピン酸エステル混合物などのエステル、オメガ3多価不飽和脂肪酸油、脂肪酸エステル、グリコールエーテル、スクアレンならびにスクアレン誘導体から選択されるベクター化化合物を含むことを特徴とする、請求項1~6のいずれか一項に記載のデバイス。
- ジフェニルリン酸エチルヘキシル、アジピン酸ジオクチル、アジピン酸ジイソオクチル、アジピン酸ジブチル、アジピン酸ジメチル、グルタル酸ジメチル、コハク酸ジメチル、またはそれらの混合物から選択される可塑化化合物を含むことを特徴とする、請求項1~7のいずれか一項に記載のデバイス。
- 首輪、ブレスレット、メダリオンまたは織物コーティングの形態で提示されることを特徴とする、請求項1~8のいずれか一項に記載のデバイス。
- 前記カンナビジオールが、CBD分離株またはCBD油の形態で存在することを特徴とする、請求項5~9のいずれか一項に記載のデバイス。
- 動物における疼痛またはストレスの緩和に使用するための活性成分を配合した、熱可塑性ポリマーマトリックスへの局所適用のためのデバイスであって、前記デバイスが、皮膚および/または毛皮と接触して配置され、前記ポリマーマトリックスが、ポリウレタンまたはエチレンビニルアセテートコポリマーから選択される少なくとも1つの非粘着性熱可塑性ポリマーを含み、前記活性成分が、デルタ-9-テトラヒドロカンナビノールを含まない少なくとも1つのカンナビジオール分離株、またはTHCを含まないカンナビジオール油、および0.5%~20%p/pの少なくとも1つの精油もしくは精油の化合物を含むことを特徴とする、デバイス。
- 腱炎、関節炎および関節症などのストレスまたは筋肉、関節もしくはリウマチ性疼痛の前記緩和に使用するための請求項11に記載のデバイス。
- ポリウレタンまたはエチレンビニルアセテートコポリマーから選択される少なくとも1つの非粘着性熱可塑性ポリマーを含む熱可塑性ポリマーマトリックスからなるデバイスを製造する方法であって、活性成分が、デルタ-9-テトラヒドロカンナビノールを含まない少なくとも1つのカンナビジオール分離株、またはデルタ-9-テトラヒドロカンナビノールを含まないカンナビジオール油、および0.5%~20%p/pの少なくとも1つの精油もしくは精油の化合物を含み、前記方法が、前記ポリマーを選択された温度に加熱するステップと、活性相を調製するステップと、前記活性相を前記ポリマーと混合するステップと、次に前記デバイスを成形するステップと、を含み、前記方法が、前記活性成分を前記ポリマーマトリックスに組み込むのを助けるための特定の賦形剤または粒子構造を添加するステップを含まないことを特徴とする、方法。
- 請求項14に記載の方法により得られた生成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866253P | 2019-06-25 | 2019-06-25 | |
US62/866,253 | 2019-06-25 | ||
US202063016374P | 2020-04-28 | 2020-04-28 | |
US63/016,374 | 2020-04-28 | ||
PCT/FR2020/000194 WO2020260777A1 (fr) | 2019-06-25 | 2020-06-25 | Dispositif sous forme de matrice polymere a base de cannabinoïdes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022540553A true JP2022540553A (ja) | 2022-09-16 |
JPWO2020260777A5 JPWO2020260777A5 (ja) | 2024-06-05 |
Family
ID=71895020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021573392A Pending JP2022540553A (ja) | 2019-06-25 | 2020-06-25 | カンナビノイド系ポリマーマトリックスの形態のデバイス |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220233433A1 (ja) |
EP (1) | EP3990024B1 (ja) |
JP (1) | JP2022540553A (ja) |
KR (1) | KR20220052309A (ja) |
ES (1) | ES2955484T3 (ja) |
WO (1) | WO2020260777A1 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2992325B1 (fr) | 2012-06-26 | 2015-05-22 | Ab7 Innovation | Matrice sequencee multifonctionnelle monopolymerique en polyurethane coule et procede de fabrication |
US20160256410A1 (en) * | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
US9827281B2 (en) * | 2015-07-24 | 2017-11-28 | Bao Tran | Medication dispensing system |
FR3039991A1 (fr) * | 2015-08-12 | 2017-02-17 | Ab7 Innovation | Composition antidouleur comprenant un derive de l'acide salicylique |
US11213558B2 (en) | 2017-05-17 | 2022-01-04 | Orochem Technologies, Inc. | CBX extraction-isolation process |
CA3077561A1 (en) * | 2018-10-15 | 2020-04-15 | Amnon VARDI | Slow release cannabinoids and products thereof |
-
2020
- 2020-06-25 JP JP2021573392A patent/JP2022540553A/ja active Pending
- 2020-06-25 ES ES20749927T patent/ES2955484T3/es active Active
- 2020-06-25 WO PCT/FR2020/000194 patent/WO2020260777A1/fr unknown
- 2020-06-25 KR KR1020217042482A patent/KR20220052309A/ko active Search and Examination
- 2020-06-25 US US17/617,470 patent/US20220233433A1/en active Pending
- 2020-06-25 EP EP20749927.8A patent/EP3990024B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
EP3990024A1 (fr) | 2022-05-04 |
US20220233433A1 (en) | 2022-07-28 |
KR20220052309A (ko) | 2022-04-27 |
EP3990024B1 (fr) | 2023-06-21 |
WO2020260777A1 (fr) | 2020-12-30 |
ES2955484T3 (es) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5694665B2 (ja) | 局所製剤とその用法 | |
DE4215677B4 (de) | Pharmazeutisches Mittel | |
Das et al. | Formulation and evaluation of herbal gel containing Clerodendron infortunatum leaves extract | |
Biswal et al. | Formulation and evaluation of microemulsion based topical hydrogel containing lornoxicam | |
US7485656B2 (en) | Antifungal remedy formulation for external application | |
FI3334433T3 (en) | Pain-killing composition comprising a salicylic acid derivative | |
JP2013507387A (ja) | 液体害虫防除配合物 | |
EP3142641A2 (de) | Formulierungen zur behandlung von hyperthyreose | |
CN104069266B (zh) | 一种兽用植物精油组合物 | |
JP2022540553A (ja) | カンナビノイド系ポリマーマトリックスの形態のデバイス | |
CN111329806A (zh) | 舒敏修复抗炎组合物及其制备方法 | |
Vishwakarma et al. | Formulation and Evaluation of Antifungal Herbal Gel Containing Ethanolic Extract of Senna Alata, Murraya Koenigii and Aloe Vera | |
JP2024521140A (ja) | 鎮痛パッチ | |
Sharma et al. | Formulation and evaluation of herbal gel containing extracts of Albezia lebbeck Linn | |
US12064461B2 (en) | Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain | |
Patil et al. | Formulation and evaluation of polyherbal anti-acne gel | |
Pabreja et al. | Evaluation of extemporaneously manufactured topical gels containing aceclofenac on inflammation and hyperalgesia in rats | |
US9867775B2 (en) | Topical pharmaceutical bases for treating inflammatory disorders | |
Mahajan et al. | Formulation and evaluation of herbal anti-inflammatory Emulgel prepared from Vitex neugondo leaves extract | |
US12059393B2 (en) | Compositions for topical treatment of radiation dermatitis | |
RU2774594C2 (ru) | Антипедикулезное лекарственное и косметическое инсектицидное средство на основе настойки чемерицы лобеля и способ его получения | |
CN100540028C (zh) | 治疗跌打损伤、风湿骨痛的涂膜剂及其制备方法 | |
JPWO2020260777A5 (ja) | ||
Remya et al. | FORMULATION AND EVALUATION OF POLYHERBAL ANTI-ACNE NANOGEL | |
ILOMUANYA et al. | African Journal of Pharmaceutical Research & Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220906 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20221118 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230411 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240226 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240910 |